Panitumumab Disease Interactions
There are 5 disease interactions with panitumumab:
EGFR inhibitors (Includes panitumumab) ↔ CV/electrolyte imbalance
Severe Potential Hazard, Moderate plausibility. Applies to: Cardiovascular Disease, Electrolyte Abnormalities, Hypokalemia, Hypocalcemia, Heart Disease, Magnesium Imbalance
The use of certain EGFR inhibitors has been associated with progressive decreases in serum magnesium levels leading to severe cases of hypomagnesemia and accompanying electrolyte abnormalities, including hypocalcemia, and hypokalemia. The onset of hypomagnesemia and accompanying electrolyte abnormalities occurred days to months after initiation of these agents. Periodically monitor patients for hypomagnesemia, hypocalcemia, and hypokalemia, during and for at least 8 weeks following the completion of therapy. Caution is recommended when using these agents in patients predisposed to electrolyte imbalances and those with a history of coronary artery disease, congestive heart failure, or arrhythmias. Replete magnesium and other electrolytes as appropriate.
EGFR inhibitors (Includes panitumumab) ↔ dermatologic toxicities
Severe Potential Hazard, Moderate plausibility. Applies to: Dermatitis - Drug-Induced
Cutaneous reactions, in some cases severe, have been reported with the use of EGFR inhibitors. Monitor patients who develop dermatologic or soft tissue toxicities while receiving these agents for the development of inflammatory or infectious sequelae. It is recommended to withhold treatment, and appropriate measures should be instituted as appropriate or discontinue the use of these agents for dermatologic or soft tissue toxicity associated with severe or life-threatening inflammatory or infectious complications. Advise patients to wear sunscreen and hats and limit sun exposure while receiving therapy with these agents as exposure to sunlight can exacerbate dermatologic toxicities.
EGFR inhibitors (Includes panitumumab) ↔ ocular disorders
Severe Potential Hazard, Moderate plausibility. Applies to: Ocular Infection
Some epidermal growth factor receptor (EGFR) inhibitors should be administered cautiously in patients with ocular disorders such as primary keratitis, ulcerative keratitis, or conjunctivitis. It is recommended to interrupt or discontinue treatment with these agents if patients present with acute or worsening ocular disorders.
EGFR inhibitors (Includes panitumumab) ↔ pulmonary toxicity
Severe Potential Hazard, Moderate plausibility. Applies to: Pulmonary Impairment, Fever
The use of certain EGFR inhibitors has been associated with pulmonary toxicity. Serious cases of interstitial lung disease (ILD), including fatal cases and interstitial pneumonitis or pulmonary fibrosis have been reported. Caution is recommended when using these agents in patients with a history of interstitial pneumonitis or pulmonary fibrosis or those patients presenting with acute onset of new or progressive unexplained pulmonary symptoms such as dyspnea, cough, and fever pending diagnostic evaluation. If ILD is confirmed, permanently discontinue these agents and institute appropriate measures.
Panitumumab (Includes panitumumab) ↔ liver/renal impairment
Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease, Renal Dysfunction
No formal pharmacokinetic studies of panitumumab have been conducted in patients with renal or hepatic impairment. Close monitoring is recommended.
Panitumumab drug interactions
There are 27 drug interactions with panitumumab
More about panitumumab
- Panitumumab Side Effects
- During Pregnancy
- Dosage Information
- Drug Interactions
- En Español
- 4 Reviews
- Drug class: EGFR inhibitors
Related treatment guides
Drug Interaction Classification
|Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.|
|Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.|
|Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.|
|No information available.|
Do not stop taking any medications without consulting your healthcare provider.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.